Total Payments
$4,944
2024 Payments
$385.43
Companies
17
Transactions
394
Medicare Patients
946
Medicare Billing
$256,821
Payment Breakdown by Category
Food & Beverage$4,756 (96.2%)
Education$188.35 (3.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,756 | 391 | 96.2% |
| Education | $188.35 | 3 | 3.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,353 | 75 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $1,005 | 144 | $0 (2021) |
| Allergan, Inc. | $746.93 | 62 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $306.53 | 25 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $296.80 | 13 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $271.42 | 15 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $256.44 | 21 | $0 (2024) |
| ITI, Inc. | $225.90 | 11 | $0 (2023) |
| Alkermes, Inc. | $112.76 | 7 | $0 (2020) |
| Lundbeck LLC | $107.82 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $385.43 | 18 | ABBVIE INC. ($115.78) |
| 2023 | $277.58 | 17 | ABBVIE INC. ($233.78) |
| 2022 | $554.41 | 22 | ABBVIE INC. ($375.72) |
| 2021 | $969.76 | 59 | AbbVie Inc. ($627.40) |
| 2020 | $659.40 | 38 | Allergan, Inc. ($348.50) |
| 2019 | $741.51 | 66 | Otsuka America Pharmaceutical, Inc. ($168.13) |
| 2018 | $388.69 | 47 | Allergan Inc. ($165.18) |
| 2017 | $967.45 | 127 | Sunovion Pharmaceuticals Inc. ($548.03) |
All Payment Transactions
394 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $21.50 | General |
| Category: Psychiatry/Psychology | ||||||
| 10/30/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $27.36 | General |
| Category: PSYCHIATRY | ||||||
| 10/24/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $31.84 | General |
| Category: Neuropsychiatry | ||||||
| 10/10/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $18.65 | General |
| Category: PSYCHIATRY | ||||||
| 07/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: NEUROSCIENCE | ||||||
| 07/19/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $19.15 | General |
| Category: PSYCHIATRY | ||||||
| 06/27/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: Neuropsychiatry | ||||||
| 06/21/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: Neurology | ||||||
| 05/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: NEUROSCIENCE | ||||||
| 04/26/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $20.88 | General |
| Category: PSYCHIATRY | ||||||
| 04/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: NEUROSCIENCE | ||||||
| 03/14/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), REXULTI | Food and Beverage | In-kind items and services | $25.47 | General |
| Category: PSYCHIATRY | ||||||
| 02/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: NEUROSCIENCE | ||||||
| 02/15/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $29.95 | General |
| Category: PSYCHIATRY | ||||||
| 02/08/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), REXULTI | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: PSYCHIATRY | ||||||
| 01/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: NEUROSCIENCE | ||||||
| 01/17/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: NEUROSCIENCE | ||||||
| 01/11/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: Neurology | ||||||
| 11/15/2023 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Neuroscience | ||||||
| 11/02/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $25.49 | General |
| Category: PSYCHIATRY | ||||||
| 11/02/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: NEUROSCIENCE | ||||||
| 09/13/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: NEUROSCIENCE | ||||||
| 08/30/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: NEUROSCIENCE | ||||||
| 08/16/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.47 | General |
| Category: NEUROSCIENCE | ||||||
| 07/27/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 171 | 705 | $156,937 | $60,921 |
| 2022 | 4 | 193 | 866 | $169,093 | $59,538 |
| 2021 | 6 | 295 | 1,072 | $140,213 | $74,202 |
| 2020 | 5 | 287 | 1,166 | $113,616 | $62,159 |
Total Patients
946
Total Services
3,809
Medicare Billing
$256,821
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 106 | 536 | $139,896 | $50,832 | 36.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 19 | 114 | $6,840 | $4,881 | 71.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 13 | $4,771 | $1,859 | 39.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 27 | $2,970 | $1,850 | 62.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 14 | 15 | $2,460 | $1,499 | 60.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 109 | 562 | $145,945 | $47,442 | 32.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 31 | 235 | $14,100 | $7,343 | 52.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 28 | 42 | $4,620 | $2,450 | 53.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 25 | 27 | $4,428 | $2,303 | 52.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 107 | 426 | $79,715 | $42,215 | 53.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 84 | 236 | $27,300 | $14,027 | 51.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 32 | 314 | $18,840 | $10,023 | 53.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 34 | 53 | $5,830 | $3,161 | 54.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 26 | 27 | $4,428 | $2,392 | 54.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 16 | $4,100 | $2,384 | 58.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 131 | 586 | $55,670 | $29,821 | 53.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 73 | 222 | $31,080 | $18,431 | 59.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 37 | 293 | $18,620 | $9,552 | 51.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 29 | 46 | $5,130 | $2,652 | 51.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 17 | 19 | $3,116 | $1,704 | 54.7% |
About Dr. Charu Patel, M.D
Dr. Charu Patel, M.D is a Psychiatry healthcare provider based in Taunton, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780644294.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charu Patel, M.D has received a total of $4,944 in payments from pharmaceutical and medical device companies, with $385.43 received in 2024. These payments were reported across 394 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($4,756).
As a Medicare-enrolled provider, Patel has provided services to 946 Medicare beneficiaries, totaling 3,809 services with total Medicare billing of $256,821. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Taunton, MA
- Active Since 03/27/2006
- Last Updated 06/06/2019
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1780644294
Products in Payments
- VRAYLAR (Drug) $2,061
- LATUDA (Drug) $973.28
- INGREZZA (Drug) $271.42
- CAPLYTA (Drug) $255.85
- INVEGA SUSTENNA (Drug) $210.86
- REXULTI (Drug) $181.43
- ABILIFY MAINTENA (Drug) $152.37
- AUSTEDO (Drug) $137.54
- ARISTADA (Drug) $101.88
- INVEGA TRINZA (Drug) $95.67
- Fanapt (Drug) $82.67
- MYRBETRIQ (Drug) $39.59
- VIIBRYD (Drug) $38.47
- VYVANSE (Drug) $34.67
- BROVANA (Drug) $31.73
- BRINTELLIX (Drug) $30.46
- UZEDY (Drug) $29.80
- Probuphine (Drug) $24.71
- COBENFY (Drug) $21.50
- SD809-TD (Drug) $18.01
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Taunton
Shalini Mansharamani, Md, MD
Psychiatry — Payments: $2,995
Psychiatry $2,995
Victor Komry, M.d, M.D
Psychiatry — Payments: $2,626
Psychiatry $2,626
Dr. Paul Weiss, M.d, M.D
Psychiatry — Payments: $935.08
Psychiatry $935.08
Gabriela Velcea, M.d, M.D
Psychiatry — Payments: $747.53
Psychiatry $747.53
Dr. Rogelio Bayog, M.d, M.D
Psychiatry — Payments: $388.57
Psychiatry $388.57
Mr. Rafael Gracia, M.d, M.D
Psychiatry — Payments: $317.14
Psychiatry $317.14